<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633269</url>
  </required_header>
  <id_info>
    <org_study_id>D0810C00010</org_study_id>
    <secondary_id>KU36-37</secondary_id>
    <nct_id>NCT00633269</nct_id>
  </id_info>
  <brief_title>Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours</brief_title>
  <official_title>Open, Non-Randomized, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]-AZD2281 (KU-0059436) in Patients With Advanced or Metastatic Solid Tumours Refractory to Standard Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KuDOS Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, non-randomized, radiolabelled, single centre study designed to characterize the
      metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg
      [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid
      tumours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours, assessed by blood, urine and faecal sampling</measure>
    <time_frame>Various timepoints</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of AZD2281 (KU-0059436) by assessment of adverse events, laboratory findings and vital signs.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide plasma and excreta samples for future studies to investigate metabolite profiles and characterize human metabolites</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To make a preliminary evaluation of clinical response as measured by objective tumour response rates at various timepoints.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2281</intervention_name>
    <description>100mg Oral Dose</description>
    <other_name>Olaparib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced or metastatic tumour, refractory to standard
             therapies

        Exclusion Criteria:

          -  Anti-cancer therapy including chemotherapy, radiotherapy (excluding palliative
             radiotherapy), endocrine therapy, immunotherapy or use of other investigational agents
             within 4 weeks prior to study entry.

          -  Patients may continue the use of LHRH agonists for cancer, bisphosphonates for bone
             disease and corticosteroids provided the dose is stable before and during the study.

          -  Females will be able to continue to take hormone replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Carmichael, BSc, MBChB, MD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>KuDOS Pharmaceuticals, Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johann deBono, MD, FRCP, MSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden Hospital, Surrey, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>January 13, 2009</last_update_submitted>
  <last_update_submitted_qc>January 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jim Carmichael - CMO</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Poly(ADP ribose) polymerases</keyword>
  <keyword>Metastatic Solid Tumours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

